NCT06682117 — Fudan University neoantigen vaccine trial
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
Registry record
| Registry ID | NCT06682117 ↗ |
|---|---|
| Lead sponsor | Fudan University |
| Collaborators | — |
| Phase | Phase NA |
| Status | Recruiting |
| Indication | Treatment, Neoantigen, Vaccine, Solid Tumor Cancer |
| Enrollment | 9 participants (target) |
| Start date | 2024-11-15 |
| Primary completion | 2026-12-30 (est.) |
| Last registry update | 2 Apr 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06682117), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06682117?
NCT06682117 (A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor) is registered on ClinicalTrials.gov as Phase NA, sponsored by Fudan University.
Is NCT06682117 recruiting?
As of the 2026-04-02 registry update, NCT06682117 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06682117?
The lead sponsor is Fudan University.
What condition does NCT06682117 study?
The registered conditions are Treatment, Neoantigen, Vaccine, Solid Tumor Cancer. Primary completion is listed as 2026-12-30 (estimated).
Are results available for NCT06682117?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06682117.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.